{"id":3339,"text":" Edited by:   Reviewed by:    This article was submitted to Drug Metabolism and Transport, a section of the journal Frontiers in Pharmacology  Background: Combination of Polygonum capitatum Buch.-Ham.","label":[],"Comments":[]}
{"id":3340,"text":"ex D. Don extract (PCE) and ciprofloxacin (CIP) was commonly prescribed in the treatment of urinary tract infections.","label":[[2,23,"Herb name"],[27,47,"Drug"],[92,116,"Pathology"]],"Comments":[]}
{"id":3341,"text":"Their pharmacokinetic herb-drug interactions (HDIs) were focused in this study to assess potential impact on the safety and effectiveness.","label":[],"Comments":[]}
{"id":3342,"text":"Methods: A randomized, three-period, crossover trial was designed to study the pharmacokinetic HDI between PCE and CIP in healthy humans.","label":[[8,53,"Study"],[107,111,"Herb name"],[115,119,"Drug"]],"Comments":[]}
{"id":3343,"text":"Their pharmacokinetic- and tissue distribution-based HDIs were also evaluated in rats.","label":[],"Comments":[]}
{"id":3344,"text":"Gallic acid (GA) and protocatechuic acid (PCA) were chosen as PK-markers of PCE in humans and rats.","label":[[0,16,"Herb name"],[21,46,"Herb name"],[76,80,"Herb name"]],"Comments":[]}
{"id":3345,"text":"Potential drug interaction mechanisms were revealed by assessing the effects of PCE on the activity and expression of multiple transporters, including OAT1\/3, OCT2, MDR1, and BCRP.","label":[[80,84,"Herb name"],[151,157,"Target"],[159,163,"Target"],[165,169,"Target"],[175,179,"Target"]],"Comments":[]}
{"id":3346,"text":"Results: Concurrent use of PCE substantially reduced circulating CIP (approximately 40%–50%) in humans and rats, while CIP hardly changed circulating GA and PCA.","label":[[26,30,"Herb name"],[65,68,"Drug"],[119,122,"Drug"],[150,152,"Herb name"],[157,160,"Herb name"]],"Comments":[]}
{"id":3347,"text":"PCE significantly increased the tissue distribution of CIP in the prostate and testis of rats, but decreased in liver and lungs.","label":[[0,4,"Herb name"],[55,59,"Drug"]],"Comments":[]}
{"id":3348,"text":"Meanwhile, CIP significantly increased the tissue distribution of GA or PCA in the prostate and testis of rats, but decreased in kidney and heart.","label":[[11,15,"Drug"],[66,69,"Herb name"],[72,76,"Herb name"]],"Comments":[]}
{"id":3349,"text":"In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1\/3 and inductive effects on MDR1 and BCRP.","label":[[42,45,"Herb name"],[49,53,"Herb name"],[84,91,"Target"],[117,121,"Target"],[125,130,"Target"]],"Comments":[]}
{"id":3350,"text":"Conclusion: Multiple transporter-mediated HDI contributes to effects of PCE on the reduced systemic exposure and altered tissue distribution of CIP.","label":[[72,76,"Herb name"],[144,147,"Drug"]],"Comments":[]}
{"id":3351,"text":"More attention should be paid on the potential for PCE-perpetrated interactions.","label":[[51,54,"Herb name"]],"Comments":[]}
{"id":3352,"text":"Communicable diseases are still leading causes of death and disability globally, according to WHO’s Global Health Estimates 2000–2019 (GBD Diseases and Injuries, 2020).","label":[[0,21,"Pathology"]],"Comments":[]}
{"id":3353,"text":"Antibiotics present a vital role in universal health insurance and global health protection.","label":[[0,11,"Drug"]],"Comments":[]}
{"id":3354,"text":"However, the clinical pipeline and recently approved antibiotics are insufficient to tackle the challenge of increasing emergence and spread of antimicrobial resistance.","label":[[53,64,"Drug"]],"Comments":[]}
{"id":3355,"text":"In recent years, traditional Chinese medicine (TCM)-based herbal therapies have been widely used to treat infectious diseases and solve the problem of microbial resistance.","label":[[29,36,"Ethnic group"],[106,125,"Pathology"]],"Comments":[]}
{"id":3356,"text":"In particular, since the outbreak of COVID-19, TCM has fully participated in the prevention, control and treatment of the epidemic and made important contributions (Huang et al., 2021).","label":[[36,45,"Pathology"]],"Comments":[]}
{"id":3357,"text":"According to the WHO Expert Meeting on Evaluation of TCM in the Treatment of COVID-19, WHO encouraged Member States to consider the integrated traditional Chinese and Western medicine model (WHO, 2022).","label":[[77,85,"Pathology"]],"Comments":[]}
{"id":3358,"text":"Polygonum capitatum Buch.-Ham.","label":[[0,29,"Herb name"]],"Comments":[]}
{"id":3359,"text":"ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).","label":[[0,24,"Herb name"],[28,36,"Ethnic group"],[93,113,"Drug"],[122,147,"Pathology"],[148,163,"Pathology"],[169,180,"Pathology"],[191,198,"Ethnic group"]],"Comments":[]}
{"id":3360,"text":"Relinqing Gallic acid (GA) and protocatechuic acid (PCA) were identified as appropriate pharmacokinetic markers (PK-markers) of P. capitatum because of their extensive pharmacological activities, high systemic exposures, and acceptable pharmacokinetic properties.","label":[[0,26,"Herb name"],[31,56,"Herb name"],[127,140,"Herb name"]],"Comments":[]}
{"id":3361,"text":"Specifically, they are the two most abundant phenolic acids in P. capitatum (Liao et al., 2013; Zhang et al., 2013a; Zhang et al., 2013b; Li et al., 2021b), and their anti-microbial, anti-inflammatory, anti-oxidant, and analgesic activities associated with P. capitatum efficacy (Liao et al., 2011; Khan et al., 2015; Choubey et al., 2018; Song et al., 2020; Bai et al., 2021).","label":[[63,76,"Herb name"],[257,270,"Herb name"]],"Comments":[]}
{"id":3362,"text":"The qualitative and quantitative analysis of PCE systemic exposure showed that GA and PCA possess a relatively high exposure in rats (Ma et al., 2015, 2016; Huang et al., 2019; Guan et al., 2022) and humans (Li et al., 2021b).","label":[[45,48,"Herb name"],[79,81,"Herb name"],[86,89,"Herb name"]],"Comments":[]}
{"id":3363,"text":"After oral administration of PCE, GA and PCA underwent a rapid absorption (Ma et al., 2015; Li et al., 2021b), a dose-dependent profile (Ma et al., 2015), and a relatively targeted distribution in kidney tissue (Ma et al., 2016).","label":[[29,32,"Herb name"],[34,36,"Herb name"],[41,45,"Herb name"]],"Comments":[]}
{"id":3364,"text":"Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.","label":[[14,17,"Herb name"],[21,25,"Herb name"],[40,44,"Herb name"]],"Comments":[]}
{"id":3365,"text":"Ciprofloxacin (CIP) was selected as a representative fluoroquinolone agent in this study because 1) it is a commonly used antibiotic in the treatment of urinary system diseases alone or in combination (Bonkat et al., 2022), and 2) it is cleared by active tubular secretion and intestinal excretion (Höffken et al., 1985; Rohwedder et al., 1990; Vance-Bryan et al., 1990).","label":[[0,19,"Drug"],[53,68,"Drug"],[122,132,"Drug"]],"Comments":[]}
{"id":3366,"text":"CIP’s absolute bioavailability is approximately 70%, with no substantial loss by first pass metabolism, and its metabolites together account for approximately 10% of an oral dose (Vance-Bryan et al., 1990).","label":[[0,3,"Drug"],[15,31,"Parameter"]],"Comments":[]}
{"id":3367,"text":"Renal clearance of CIP accounts for 2\/3 of its total clearance and exceeds the normal glomerular filtration rate, suggesting that active tubular secretion may play a role (Höffken et al., 1985; Mulgaonkar et al., 2012).","label":[[0,15,"Parameter"],[19,22,"Drug"],[86,112,"Parameter"]],"Comments":[]}
{"id":3369,"text":"Approximately 20% of an intravenous dose of CIP is eliminated into the intestine (Rohwedder et al., 1990; Haslam et al., 2011).","label":[[43,47,"Drug"]],"Comments":[]}
{"id":3368,"text":"Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).","label":[[21,24,"Drug"]],"Comments":[]}
{"id":3370,"text":"At physiological pH = 7.4, CIP predominantly exists as a zwitterion indicating that both anion and cation transporters may contribute to its excretion (Vanwert et al., 2008; Haslam et al., 2011; Arakawa et al., 2012; Mulgaonkar et al., 2012).","label":[[27,30,"Drug"]],"Comments":[]}
{"id":3383,"text":"Stably expressing cell lines of hOAT1-MDCK, hOAT3-MDCK, hOCT2-S2, hMDR1-MDCK, hBCRP-MDCK, and their mock cells were obtained from Japan Fuji Biomedical Co., Ltd.","label":[],"Comments":[]}
{"id":3384,"text":"The cells were maintained in DMEM (Sigma) supplemented with 10% FCS, 1% non-essential amino acids (Sigma), and 2% L-glutamine.","label":[],"Comments":[]}
{"id":3385,"text":"The medium for the Transwell Briefly, the hOAT1-MDCK, hOAT3-MDCK, and hOCT2-S2 cells were trypsinized and suspended in the culture medium to provide a density of 1.5 × 10 A bidirectional assay in Caco-2 cells is a preferred method to determine whether an investigational drug is a substrate for P-gp\/BCRP or whether an investigational drug is an inhibitor of P-gp\/BCRP (US FDA, 2020).","label":[],"Comments":[]}
{"id":3371,"text":"CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).","label":[[0,3,"Drug"]],"Comments":[]}
{"id":3372,"text":"Overall, drug transporter-mediated HDIs were assessed to reveal the altered systemic exposure and tissue distribution of CIP after combined treatment with PCE in this study.","label":[[76,93,"Parameter"],[121,124,"Drug"],[155,159,"Herb name"]],"Comments":[]}
{"id":3373,"text":"Relinqing Twelve healthy male volunteers aged 18–35 years who weighed at least 50 kg and had a body mass index of 19–24 kg\/m A randomized, three-period, crossover trial was designed to study the herb-drug interactions in healthy male subjects following the administration of single-dose treatments with PCE (8 g Relinqing Schematic illustration of the study design in healthy subjects.","label":[[10,40,"Cohort"],[17,24,"Pathology"],[25,29,"Sex"],[45,57,"Age"],[62,69,"Parameter"],[79,84,"Amount"],[95,110,"Parameter"],[114,124,"Amount"],[126,168,"Study"],[221,228,"Pathology"],[229,233,"Sex"],[274,286,"Frequency"],[303,307,"Herb name"],[367,375,"Pathology"]],"Comments":[]}
{"id":3374,"text":"Male Sprague-Dawley rats weighing 200–220 g were purchased from HFK Bioscience Co., Ltd. (SCXK 2019–0008, Beijing, China).","label":[],"Comments":[]}
{"id":3375,"text":"All of the experimental procedures were carried out according to the Guidance for Ethical Treatment of Laboratory Animals.","label":[],"Comments":[]}
{"id":3376,"text":"Approval for this study was granted by the Institutional Animal Care and Use Committee of Tianjin University of Traditional Chinese Medicine.","label":[[124,131,"Ethnic group"]],"Comments":[]}
{"id":3377,"text":"All animals were housed at the individually ventilated cages (three rats per cage) in a temperature-controlled room under a 12-h light\/dark cycle.","label":[],"Comments":[]}
{"id":3378,"text":"Water and food were supplied ad libitum and the rats were fasted only with free access to water for 12 h prior to experiment.","label":[],"Comments":[]}
{"id":3379,"text":"In the pharmacokinetic-HDI study, eighteen rats were randomly assigned to three experimental groups (n = 6 per group).","label":[[7,32,"Study"]],"Comments":[]}
{"id":3380,"text":"Rats in the PCE, CIP, and PCE + CIP groups were orally given a single dose of PCE (0.72 g\/kg, comparable to a clinical dose of 8 g Relinqing In the tissue distribution-HDI study, thirty-six rats were randomly assigned to three experimental groups (n = 12 per group).","label":[[12,15,"Herb name"],[17,20,"Drug"],[25,29,"Herb name"],[32,35,"Drug"],[61,74,"Frequency"],[78,81,"Herb name"],[83,92,"Amount"],[148,177,"Study"]],"Comments":[]}
{"id":3381,"text":"Rats in the PCE, CIP, and PCE + CIP groups were given a single dose of PCE (0.72 g\/kg, comparable to a clinical dose of 8 g Relinqing Considering the relative exposure characteristics, GA and PCA were selected as PK-marker and Q-marker components of PCE in previous studies (Ma et al., 2015; Ma et al., 2016; Li et al., 2021b).","label":[[12,15,"Herb name"],[17,20,"Drug"],[26,29,"Herb name"],[32,35,"Drug"],[56,68,"Frequency"],[76,85,"Amount"],[120,124,"Amount"],[185,187,"Herb name"],[192,195,"Herb name"],[250,253,"Herb name"]],"Comments":[]}
{"id":3382,"text":"In this study, we investigated the concentration-dependent inhibitions of GA and PCA on multiple transporters, including OAT1, OAT3, OCT2, MDR1, and BCRP.","label":[[74,76,"Herb name"],[81,84,"Herb name"],[121,125,"Target"],[127,131,"Target"],[133,137,"Target"],[139,143,"Target"],[148,153,"Target"]],"Comments":[]}
{"id":3386,"text":"The Caco-2 cell lines were obtained from the National Collection of Authenticated Cell Cultures (NCACC, Shanghai, China).","label":[],"Comments":[]}
{"id":3387,"text":"The bi-directional transport assay was performed on 12-mm Transwell Permeable Supports with 0.4 mm-pore polycarbonate membrane insert and 1.12 cm Caco-2 cells induced with the positive control or tested drugs were then incubated in a 37°C incubator with 5% CO The tissue samples were homogenized using a tissue homogenizer (JXFSTPRP-24, Shanghaijingxin Experimental Technology, Shanghai, China) in physiological saline solution (1:4, w\/v).","label":[],"Comments":[]}
{"id":3388,"text":"The analytes and internal standards were extracted from tissue homogenates and plasma samples by a simple protein precipitation method.","label":[],"Comments":[]}
{"id":3389,"text":"Briefly, an aliquot of 100 μl biological samples, 5 μl internal standard solutions, and 300 μl acetonitrile were vortex-mixed for 3 min and then centrifuged at 14,000 rpm for 10 min.","label":[],"Comments":[]}
{"id":3391,"text":"The residues were reconstituted with 100 μl of 20% acetonitrile solution, vortex-mixed for 1 min, and centrifugated at 14,000 rpm for 10 min.","label":[],"Comments":[]}
{"id":3393,"text":"Samples were analyzed using a Waters ACQUITY™ ultra performance liquid chromatography system (Waters Corp., Milford, MA, United States) equipped with an QTRAP5500 triple-quadrupole mass spectrometer (SCIEX, Framingham, MA, United States) and an electrospray source.","label":[],"Comments":[]}
{"id":3394,"text":"Data acquisition was controlled by Analyst 1.7.2 software (SCIEX, Concord, ON, Canada).","label":[],"Comments":[]}
{"id":3395,"text":"Chromatographic separation of GA and PCA was achieved on an ACQUITY UPLC BEH C18 (2.1 mm × 100 mm, 1.7 µm; Waters Corp., Milford, MA, United States) with a mobile phase of (A) 0.1% formic acid aqueous solution and (B) 0.1% formic acid acetonitrile at a flow rate of 0.3 ml\/min.","label":[[30,32,"Herb name"],[37,40,"Herb name"]],"Comments":[]}
{"id":3396,"text":"The gradient elution program was as follows: 0–8.5 min, 97% A; 8.7–11 min, 60% A; 11.5–13.5 min, 10% A; 14–15 min, 97% A.","label":[],"Comments":[]}
{"id":3397,"text":"The quantitation of GA and PCA was performed using multiple reaction monitoring (MRM) mode with an electron spray ionization (ESI) source in negative-ionization mode.","label":[[20,22,"Herb name"],[27,30,"Herb name"]],"Comments":[]}
{"id":3399,"text":"The precursor-product ion transitions of GA, PCA, and chloramphenicol (internal standard) were 169.0→125.1, 153.1→109.0, and 321.1→152.1, respectively.","label":[[41,43,"Herb name"],[45,48,"Herb name"],[54,70,"Drug"]],"Comments":[]}
{"id":3390,"text":"The supernatant was transferred and dried using a gentle stream of nitrogen at 35°C.","label":[],"Comments":[]}
{"id":3392,"text":"The supernate was utilized for the quantification of GA, PCA, and CIP.","label":[[53,55,"Herb name"],[57,60,"Herb name"],[65,69,"Drug"]],"Comments":[]}
{"id":3398,"text":"The source operation parameters were optimized as follows: ion spray voltage, −4,500 V; source temperature, 550°C; ion source gas1, 55 psi; ion source gas2, 60 psi; curtain gas, 35 psi.","label":[],"Comments":[]}
{"id":3400,"text":"The separation of CIP was performed on the same column and mobile phase as GA and PCA.","label":[[18,22,"Drug"],[75,78,"Herb name"],[82,85,"Herb name"]],"Comments":[]}
{"id":3401,"text":"The gradient elution program was as follows: 0–2.5 min, 85% A; 3–4 min, 10% A; 4.5–6 min, 85% A; 14–15 min, 97% A.","label":[],"Comments":[]}
{"id":3402,"text":"The quantitation of CIP was performed using MRM mode with an ESI source in positive-ionization mode.","label":[[20,24,"Drug"]],"Comments":[]}
{"id":3403,"text":"The source parameters were chosen as follows: ion spray voltage, 5,500 V; source temperature, 450°C; ion source gas1, 50 psi; ion source gas2, 50 psi; curtain gas, 35 psi.","label":[],"Comments":[]}
{"id":3404,"text":"The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1→288.1 and 362.2→318.1, respectively.","label":[[41,44,"Drug"],[49,58,"Drug"]],"Comments":[]}
{"id":3405,"text":"PK parameters were estimated with noncompartmental methods using WinNonlin version 6.4 (Certara, Princeton, NJ).","label":[],"Comments":[]}
{"id":3406,"text":"The peak plasma concentration (C  All data were summarized as mean ± standard deviation (SD).","label":[],"Comments":[]}
{"id":3407,"text":"All statistical analyses were performed using SPSS software (Chicago, IL, United States).","label":[],"Comments":[]}
{"id":3408,"text":"Comparisons between groups were performed using unpaired Student’s t-test.","label":[],"Comments":[]}
{"id":3409,"text":"A p-value of less than 0.05 was considered statistically significant.","label":[],"Comments":[]}
{"id":3410,"text":"Pharmacokinetic interactions were reported as 90% confidence intervals (CI) for the geometric mean ratios (GMR) of the observed pharmacokinetic measures in the presence and absence of the interacting drug.","label":[],"Comments":[]}
{"id":3411,"text":"If the 90% CI for systemic exposure ratios was entirely encompassed within the equivalence range of 0.80–1.25, we concluded that clinically significant difference was not present.","label":[],"Comments":[]}
{"id":3412,"text":"All recruited subjects were healthy Chinese natives.","label":[[28,36,"Pathology"],[36,43,"Ethnic group"]],"Comments":[]}
{"id":3413,"text":"All enrolled subjects completed the study protocol as planned.","label":[],"Comments":[]}
{"id":3414,"text":"Their age, height, weight, and body mass index were summarized in Supplementary Table S1.","label":[[11,17,"Parameter"],[19,25,"Parameter"],[31,46,"Parameter"]],"Comments":[]}
{"id":3415,"text":"No major protocol deviations were identified, and no serious adverse reactions were observed throughout the study.","label":[[61,79,"Pathology"]],"Comments":[]}
{"id":3416,"text":"The effects of PCE on CIP plasma concentrations were investigated by comparing alterations in PK exposure measures between control and treatment groups.","label":[[15,18,"Herb name"],[21,25,"Drug"]],"Comments":[]}
{"id":3417,"text":"The CIP concentration-time profiles and PK parameters are shown in Figure 2A and Table 1, respectively.","label":[[4,7,"Drug"]],"Comments":[]}
{"id":3419,"text":"Median (range).","label":[],"Comments":[]}
{"id":3420,"text":"PCE Multiple doses of PCE (8 g, TID) for seven consecutive days.","label":[[0,3,"Herb name"],[22,25,"Herb name"],[27,30,"Amount"],[41,63,"Duration"]],"Comments":[]}
{"id":3418,"text":"The plasma ciprofloxacin AUC  Plasma ciprofloxacin (CIP) concentration-time profiles (A), the systemic exposure parameters including AUC  Pharmacokinetic parameters of ciprofloxacin after the oral administration of ciprofloxacin hydrochloride tablets (CIP, 0.5 g) with and without PCE (8 g) to human subjects (mean ± SD, n = 12).","label":[[11,25,"Drug"],[25,28,"Parameter"],[37,57,"Drug"],[133,136,"Parameter"],[168,181,"Drug"],[214,228,"Drug"],[252,256,"Drug"],[257,262,"Amount"],[280,285,"Herb name"],[286,289,"Amount"]],"Comments":[]}
{"id":3421,"text":"*p< 0.05, significant differences were observed when compared with the CIP, group.","label":[[70,74,"Drug"]],"Comments":[]}
{"id":3422,"text":"GA and PCA were identified as PK-markers of PCE to present the effects of CIP on PCE systemic exposures.","label":[[0,2,"Herb name"],[7,10,"Herb name"],[44,47,"Herb name"],[74,77,"Drug"],[81,84,"Herb name"]],"Comments":[]}
{"id":3423,"text":"After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.","label":[[27,31,"Drug"],[34,38,"Herb name"],[58,60,"Herb name"],[64,68,"Herb name"]],"Comments":[]}
{"id":3424,"text":"Their PK parameters (Table 2) were calculated from the plasma concentration-time curves (Figures 3A, 4A).","label":[],"Comments":[]}
{"id":3425,"text":"No significant differences between control and combination treatment groups were observed on the systemic exposure parameters of GA (Figures 3B,C) and PCA (Figures 4B,C).","label":[[129,131,"Herb name"]],"Comments":[]}
{"id":3426,"text":"Following co-treatment with CIP and a single dose of PCE, the GMRs ±90% CI of GA AUC  Plasma gallic acid (GA) concentration-time profiles (A), the systemic exposure parameters of GA including AUC  Plasma protocatechuic acid (PCA) concentration-time profiles (A), the systemic exposure parameters of PCA including AUC  Pharmacokinetic parameters of gallic acid (GA) and protocatechuic acid (PCA) after the oral administration of PCE (8 g) with and without ciprofloxacin hydrochloride tablets (CIP, 0.5 g) to human subjects (mean ± SD, n = 12).","label":[[28,31,"Drug"],[52,56,"Herb name"],[78,80,"Herb name"],[81,93,"Parameter"],[92,110,"Herb name"],[179,181,"Herb name"],[192,204,"Parameter"],[204,229,"Herb name"],[298,302,"Herb name"],[313,316,"Parameter"],[347,364,"Herb name"],[368,395,"Herb name"],[427,431,"Herb name"],[433,436,"Amount"],[455,468,"Drug"],[492,495,"Drug"],[497,502,"Amount"]],"Comments":[]}
{"id":3427,"text":"Median (range).","label":[],"Comments":[]}
{"id":3429,"text":"No significant differences were observed when compared with the PCE The effects of PCE on circulating CIP concentrations were observed by comparing changes in PK exposure measures between CIP and CIP + PCE groups.","label":[[64,67,"Herb name"],[83,87,"Herb name"],[102,105,"Drug"],[188,191,"Drug"],[195,200,"Drug"],[202,205,"Herb name"]],"Comments":[]}
{"id":3430,"text":"The CIP concentration-time profiles and PK parameters are presented in Figure 5A and Table 3, respectively.","label":[[4,7,"Drug"]],"Comments":[]}
{"id":3431,"text":"The AUC  Circulating ciprofloxacin (CIP) concentration-time profiles (A) and the 90% confidence intervals (CI) for the geometric mean ratios [GMR, (B)] of C  Pharmacokinetic parameters of ciprofloxacin after intragastric administration of ciprofloxacin (CIP, 0.045 g\/kg) with and without PCE (0.72 g\/kg) to rats (mean ± SD, n = 6).","label":[[4,8,"Parameter"],[21,40,"Drug"],[188,201,"Drug"],[239,252,"Drug"],[254,257,"Drug"],[259,269,"Amount"],[288,291,"Herb name"],[293,302,"Amount"]],"Comments":[]}
{"id":3432,"text":"Median (range).","label":[],"Comments":[]}
{"id":3433,"text":"*p< 0.05, significant differences were observed when compared with the CIP, group.","label":[[70,74,"Drug"]],"Comments":[]}
{"id":3434,"text":"After combination therapy, the altered circulating exposures of PCE PK-markers (GA and PCA) are shown in Figures 5C–F.","label":[[63,67,"Herb name"],[80,83,"Herb name"],[87,90,"Herb name"]],"Comments":[]}
{"id":3435,"text":"The PK parameters of GA and PCA are summarized in Table 4.","label":[[21,23,"Herb name"],[28,31,"Herb name"]],"Comments":[]}
{"id":3428,"text":"PCE Multiple doses of PCE (8 g, TID) for seven consecutive days.","label":[[0,3,"Herb name"],[22,25,"Herb name"],[27,30,"Amount"],[41,63,"Duration"]],"Comments":[]}
{"id":3436,"text":"No significant differences between PCE and PCE + CIP groups were observed on the main PK parameters of GA and PCA.","label":[[35,38,"Herb name"],[42,46,"Herb name"],[49,52,"Drug"],[103,105,"Herb name"],[110,113,"Herb name"]],"Comments":[]}
{"id":3437,"text":"After co-treatment with CIP and PCE, the GMRs ±90% CI of GA AUC  Pharmacokinetic parameters of gallic acid and protocatechuic acid after intragastric administration of PCE (0.72 g\/kg) with and without ciprofloxacin (CIP, 0.045 g\/kg) to rats (mean ± SD, n = 6).","label":[[23,27,"Drug"],[32,35,"Herb name"],[57,59,"Herb name"],[60,64,"Parameter"],[95,107,"Herb name"],[111,131,"Herb name"],[168,172,"Herb name"],[173,182,"Amount"],[201,215,"Drug"],[216,219,"Drug"],[221,231,"Amount"]],"Comments":[]}
{"id":3438,"text":"Median (range).","label":[],"Comments":[]}
{"id":3439,"text":"No significant differences were observed when compared with the PCE, group (p > 0.05).","label":[[64,67,"Herb name"]],"Comments":[]}
{"id":3440,"text":"PCE had little effect on plasma CIP after intravenous injection using rats (Supplementary Figure S1; Supplementary Table S2).","label":[[0,3,"Herb name"],[32,36,"Drug"]],"Comments":[]}
{"id":3441,"text":"The tissue distribution profiles of CIP in normal rats after intravenous administration of CIP in the absence and presence of PCE are charted in Figures 6A,B, respectively.","label":[[36,39,"Drug"],[91,94,"Drug"],[126,129,"Herb name"]],"Comments":[]}
{"id":3442,"text":"PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.","label":[[0,3,"Herb name"],[111,130,"Drug"],[167,170,"Drug"],[210,213,"Herb name"],[319,321,"Herb name"],[374,377,"Herb name"],[408,413,"Drug"]],"Comments":[]}
{"id":3443,"text":"CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.","label":[[0,3,"Drug"],[67,83,"Herb name"],[113,116,"Herb name"],[156,169,"Drug"],[267,270,"Herb name"],[303,306,"Drug"]],"Comments":[]}
{"id":3444,"text":"CIP did not significantly alter the K  Tissue distribution profiles of protocatechuic acid (PCA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  Significant inhibitory effects of the positive inhibitors of probenecid, cimetidine, rifampicin, verapamil, and cyclosporine were presented on the transporters hOAT1, hOAT3, hOCT2, hMDR1, and hBCRP, respectively (Supplementary Figure S2).","label":[[0,3,"Drug"],[71,96,"Herb name"],[125,129,"Herb name"],[168,182,"Drug"],[307,317,"Drug"],[319,329,"Drug"],[331,341,"Drug"],[343,352,"Drug"],[358,370,"Drug"],[406,411,"Target"],[413,418,"Target"],[420,425,"Target"],[427,432,"Target"],[438,443,"Target"]],"Comments":[]}
{"id":3445,"text":"A concentration-dependent inhibition type was observed on the transporters hOAT1 and hOAT3 for GA, as well as the transporters hOAT1, hOAT3 and hOCT2 for PCA (Figures 9A–C).","label":[[75,80,"Target"],[85,90,"Target"],[94,97,"Herb name"],[127,132,"Target"],[133,139,"Target"],[144,150,"Target"],[154,157,"Herb name"]],"Comments":[]}
{"id":3446,"text":"GA and PCA presented significant inhibitory effects on the hOAT1-mediated uptake of  Inhibitory effects of GA and PCA on the activity of multiple transporters, including human organic anion transporter 1 [hOAT1, (A)], [hOAT3 (B)], human organic cation transporter 2 [hOCT2, (C)], human multidrug resistance protein 1 [hMDR1, (D)], and human breast cancer resistance protein [hBCRP, (E)] (mean ± SD, n = 3).","label":[[0,2,"Herb name"],[7,10,"Herb name"],[59,64,"Target"],[107,109,"Herb name"],[114,117,"Herb name"],[170,210,"Target"],[219,224,"Target"],[231,273,"Target"],[280,324,"Target"],[335,381,"Target"]],"Comments":[]}
{"id":3447,"text":"In the bidirectional transport assay with Caco-2 cells, the net flux ratio of CIP after 0.5 and 1 h were 4.13 ± 0.76 and 3.48 ± 0.10, respectively.","label":[[77,81,"Drug"]],"Comments":[]}
{"id":3448,"text":"After co-incubation with GA, PCA and PCE, the net flux ratio of CIP showed varying degrees of enlargement (Figures 10A,B).","label":[[25,27,"Herb name"],[29,32,"Herb name"],[37,40,"Herb name"],[64,67,"Drug"]],"Comments":[]}
{"id":3449,"text":"A significant improvement was observed in the net efflux ratios after co-treatment with GA (50 μM), PCA (50 μM), and PCE (100 mg\/ml) (p < 0.05).","label":[[88,90,"Herb name"],[100,103,"Herb name"],[116,120,"Herb name"]],"Comments":[]}
{"id":3450,"text":"The increased net flux ratio facilitates the flow of CIP from the blood to the intestinal lumen, renal tubules or bile ducts, which may be related to the reduction of CIP systemic exposure.","label":[[53,56,"Drug"],[167,170,"Drug"]],"Comments":[]}
{"id":3452,"text":"The effect of PCE on the expression of MDR1 and BCRP mRNAs are shown in Figures 10C,D, respectively.","label":[[14,17,"Herb name"],[39,43,"Target"],[47,52,"Target"]],"Comments":[]}
{"id":3453,"text":"After pretreatment with bosentan, the expression of P-gp and BCRP mRNAs in Caco-2 cells were increased by 7.36- and 4.31-fold, respectively.","label":[[24,33,"Drug"],[52,56,"Target"],[61,71,"Target"]],"Comments":[]}
{"id":3454,"text":"After pretreatment with the investigated drugs, the expression of MDR1 and BCRP mRNAs increased 6.02- and 6.00-fold in cells treated with GA, 3.56- and 3.33-fold in cells treated with PCA, and 4.04- and 3.95-fold in cells treated with PCE, respectively.","label":[[65,70,"Target"],[75,85,"Target"],[138,140,"Herb name"],[184,187,"Herb name"],[235,238,"Herb name"]],"Comments":[]}
{"id":3455,"text":"The increased MDR1 and BCRP mRNA expressions may contribute to CIP efflux from the blood circulatory system.","label":[[13,18,"Target"],[23,33,"Target"],[63,66,"Drug"]],"Comments":[]}
{"id":3457,"text":"Thereafter, due to the pharmacokinetic- and pharmacodynamic-based HDIs, the concurrent use of herbal medicinal products may mimic, magnify, or oppose the effects of medicinal products (Fugh-Berman, 2000).","label":[],"Comments":[]}
{"id":3458,"text":"Pharmacokinetic HDIs may increase or decrease the systemic exposures of either component through multiple mechanisms, including drug-metabolizing enzymes (e.g., CYP450s and UGTs), drug transporters (e.g., P-gp and BCRP) and plasma protein (e.g., albumin and globulin), which is basically similar to pharmacokinetic DDIs (Li et al., 2019).","label":[],"Comments":[]}
{"id":3451,"text":"Effects of gallic acid (GA), protocatechuic acid (PCA) and PCE on the change of ciprofloxacin efflux ratios at 0.5 h (A) and 1 h (B), and the mRNA expressions of MDR1 (C) and BCRP (D) in Caco-2 cells (mean ± SD, n = 3).","label":[[10,27,"Herb name"],[29,54,"Herb name"],[59,62,"Herb name"],[80,94,"Drug"],[161,166,"Target"],[175,179,"Target"]],"Comments":[]}
{"id":3456,"text":"Herbal medicinal products are commonly used as a complementary or alternative treatment for a variety of diseases, rehabilitation and health care (Meng and Liu, 2014).","label":[],"Comments":[]}
{"id":3459,"text":"Nevertheless, the research of pharmacokinetic HDIs is generally more challenging than that of DDIs, given the complicated herbal components and the batch-to-batch variation of herbal medicines (Meng and Liu, 2014).","label":[],"Comments":[]}
{"id":3460,"text":"This has led to a phenomenon that most of the current studies pay more attention to the unidirectional effect (herbs→drugs) than the bidirectional effect (herbs↔drugs).","label":[],"Comments":[]}
{"id":3461,"text":"Even though, the pharmacokinetic HDIs between PCE and CIP were investigated on a bidirectional effect (PCE↔CIP) in this study.","label":[[46,49,"Herb name"],[54,58,"Drug"],[103,106,"Drug"],[107,110,"Drug"]],"Comments":[]}
{"id":3462,"text":"GA and PCA were identified as appropriate PK-marker components of P. capitatum because of 1) their extensive pharmacological activities consistent with P. capitatum (Liao et al., 2011; Khan et al., 2015; Choubey et al., 2018; Song et al., 2020; Bai et al., 2021), 2) their rich in vitro (Liao et al., 2013; Zhang et al., 2013a; Zhang et al., 2013b; Li et al., 2021b) and in vivo exposures (Ma et al., 2015, 2016; Huang et al., 2019; Li et al., 2021b; Guan et al., 2022), and 3) their acceptable pharmacokinetic properties (Ma et al., 2015; Li et al., 2021b) and targeted distribution in kidney tissue (Ma et al., 2016).","label":[[0,2,"Herb name"],[7,11,"Herb name"],[66,79,"Herb name"],[152,164,"Herb name"]],"Comments":[]}
{"id":3463,"text":"However, there is a risk that the two compounds were possibly not the most critical compounds responsible for PCE’s effect, and the use of any single compound of the two compounds in the study could not reflect the overall effect of PCE.","label":[[110,115,"Herb name"],[232,236,"Herb name"]],"Comments":[]}
{"id":3465,"text":"Although herbal crude extract has been used as perpetrator in some cell experiments, false positive or false negative results will inevitably occur (Ge et al., 2010).","label":[],"Comments":[]}
{"id":3466,"text":"The main reasons include but are not limited to the following aspects.","label":[],"Comments":[]}
{"id":3467,"text":"PCE addition can alter some extracellular characteristics, such as pH value and ionic strength.","label":[[0,4,"Herb name"]],"Comments":[]}
{"id":3468,"text":"PCE contains some components that are not absorbed into blood when administered orally, which may interfere with cultured cells.","label":[[0,4,"Herb name"]],"Comments":[]}
{"id":3469,"text":"Despite serum pharmacological method can solve the above problems, preparation of test serum for cell experiment is a complicated process: Besides chemicals or heat pretreatment, it involves the proteolytic cascades of coagulation along with complement, fibrinolysis and kinin systems, as well as leukocyte and platelet activation resulting in release reactions (Ge et al., 2010).","label":[],"Comments":[]}
{"id":3470,"text":"The pretreatment deviates serum sample elements away from the original in vivo state.","label":[],"Comments":[]}
{"id":3472,"text":"Considering GA and PCA are highly exposed in plasma and urogenital system tissues, we examined the inhibitory effects of the two components on the activity of multiple transporters that mediate CIP transport.","label":[[12,15,"Herb name"],[19,23,"Herb name"],[19,23,"Herb name"],[19,23,"Herb name"],[194,198,"Drug"]],"Comments":[]}
{"id":3473,"text":"The shortcomings of using these two compounds are the same as those of using PK-markers.","label":[],"Comments":[]}
{"id":3474,"text":"Clinical evidence showed that combination of PCE and CIP could produce a better effect for the treatment of chronic prostatitis (Zhou et al., 2016) and urinary tract infections (Pu et al., 2016).","label":[[45,49,"Herb name"],[53,57,"Drug"],[108,127,"Pathology"],[152,176,"Pathology"]],"Comments":[]}
{"id":3475,"text":"However, since co-administration of PCE significantly reduces plasma CIP in human (Figure 2), the results seemed not to support such an effect.","label":[[36,40,"Herb name"],[69,73,"Drug"]],"Comments":[]}
{"id":3464,"text":"Since CIP is a substrate of multiple transporters, the drug-transporter mediated inhibition test was performed to study the responsibilities for the reduced CIP exposure.","label":[[6,9,"Drug"],[157,161,"Drug"]],"Comments":[]}
{"id":3471,"text":"The results obtained from the drug-containing serum are at least partially uncertain in its validity.","label":[],"Comments":[]}
{"id":3476,"text":"Interestingly, we found that the combined therapy significantly increased the exposure of CIP in the prostate (Figure 6), which may be the target tissue for the treatment of chronic prostatitis (Lipsky et al., 2010).","label":[[90,94,"Drug"],[174,193,"Pathology"]],"Comments":[]}
{"id":3477,"text":"In addition to CIP, GA and PCA (PCE PK-markers) presented high exposure in the urogenital system, such as prostate, kidney, and seminal vesicle gland (Figures 7, 8).","label":[[15,18,"Drug"],[20,22,"Herb name"],[26,30,"Herb name"],[32,36,"Herb name"]],"Comments":[]}
{"id":3478,"text":"The antibacterial, anti-inflammatory, antioxidant and analgesic activities of PCE, GA and PCA are helpful to improve the efficacy of CIP in the treatment of infectious diseases of urogenital system (Liao et al., 2011; Khan et al., 2015; Choubey et al., 2018; Song et al., 2020; Bai et al., 2021).","label":[[78,81,"Herb name"],[83,86,"Herb name"],[90,94,"Herb name"],[133,136,"Drug"],[157,197,"Pathology"]],"Comments":[]}
{"id":3479,"text":"The in vitro study proves that PCA increased up to 50% of the antibacterial activity, especially that of levofloxacin against Staphylococcus aureus and Escherichia coli (Fifere et al., 2022).","label":[[31,35,"Herb name"],[105,118,"Drug"]],"Comments":[]}
{"id":3481,"text":"Considering the manner in which the drug is removed from the body, CIP is primarily cleared by active tubular secretion (up to 2\/3 of the total clearance, Höffken et al., 1985; Mulgaonkar et al., 2012) and intestinal excretion (approximately 18%, Rohwedder et al., 1990).","label":[[67,71,"Drug"]],"Comments":[]}
{"id":3482,"text":"Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.","label":[[170,174,"Drug"],[223,227,"Drug"]],"Comments":[]}
{"id":3483,"text":"CIP is a known substrate of the ATP-binding cassette transporters BCRP (Alvarez et al., 2008; Haslam et al., 2011) and MDR1 (Brillault et al., 2010; Arakawa et al., 2012; Zhang et al., 2019; Zimmermann et al., 2019), both of which are located in the apical (luminal) membrane of kidney proximal tubules and intestinal epithelia (International Transporter Consortium, 2010).","label":[[0,4,"Drug"],[65,70,"Target"],[119,123,"Target"]],"Comments":[]}
{"id":3484,"text":"The reduced circulating CIP in humans may be attributed to the increased BCRP\/MDR1-mediated CIP efflux from blood to feces and urine, as indicated by the effects of PCE, GA and PCA on CIP bidirectional transport and BCRP\/MDR1 expressions in this study.","label":[[24,28,"Drug"],[73,95,"Target"],[92,95,"Drug"],[165,168,"Herb name"],[170,172,"Herb name"],[176,180,"Herb name"],[184,187,"Drug"],[216,225,"Target"]],"Comments":[]}
{"id":3485,"text":"Due to the zwitterionic nature, CIP is likely to interact with organic anion and cation transporters, such as OAT1, OAT3, and OCT2 (Dautrey et al., 1999; Vanwert et al., 2008; Arakawa et al., 2012; Mulgaonkar et al., 2012; Ong et al., 2013).","label":[[32,36,"Drug"],[110,114,"Target"],[116,120,"Target"],[126,130,"Target"]],"Comments":[]}
{"id":3486,"text":"But the inhibitory effects of GA and PCA on OAT1\/3-mediated CIP secretion from blood to feces and urine did not contribute to the reduced circulating CIP in humans.","label":[[29,32,"Herb name"],[37,40,"Herb name"],[37,40,"Herb name"],[43,64,"Target"],[60,64,"Drug"],[150,153,"Drug"]],"Comments":[]}
{"id":3487,"text":"That is, the decrease of CIP systematic exposure in the combined group was caused by the integrated effect of synergy\/antagonism among multiple transporters.","label":[[25,28,"Drug"]],"Comments":[]}
{"id":3488,"text":"Additionally, the reduced circulating CIP may also come from other transporter-mediated interactions (eg., OATPs, MRPs, Wu et al., 2012; Marquez et al., 2009), drug metabolizing enzyme-mediated interactions (eg., CYP450, Zheng et al., 2014), and other PCE composition-perpetrated interactions (eg., flavonoids, An et al., 2014).","label":[[38,42,"Drug"],[107,112,"Target"],[114,118,"Target"],[252,255,"Herb name"]],"Comments":[]}
{"id":3489,"text":"Tissue distribution-based HDI studies were also implemented to assess the effects of combination therapy on the altered distribution kinetics of CIP, GA, and PCA, which may directly or indirectly lead to changes in their therapeutic effect.","label":[[145,148,"Drug"],[150,152,"Herb name"],[158,161,"Herb name"]],"Comments":[]}
{"id":3490,"text":"The combined administration increased CIP exposure in the prostate, testis, and seminal vesicle gland, which may help to treat infectious diseases of the male reproductive system.","label":[[38,42,"Drug"],[127,147,"Drug"]],"Comments":[]}
{"id":3491,"text":"As summarized by Obligacion et al.","label":[],"Comments":[]}
{"id":3480,"text":"Concurrent use of PCE significantly reduced circulating CIP in humans and rats, consistent with previous reports (Lu et al., 2016).","label":[[18,22,"Herb name"],[56,60,"Drug"]],"Comments":[]}
{"id":3492,"text":"(2006), the human prostate tissue contains the multidrug resistance protein (MRP) transporters MRP1, MRP2, MRP3, and MRP4, and MDR1.","label":[],"Comments":[]}
{"id":3493,"text":"Thus, the increased distribution of CIP in the prostate gland may be attributed to the activation of MRPs and MDR1 after treated with GA and PCA.","label":[[36,40,"Drug"],[101,106,"Target"],[110,115,"Target"],[134,137,"Herb name"],[141,144,"Herb name"]],"Comments":[]}
{"id":3494,"text":"Although no significant alteration in the circulating GA and PCA after combination therapy, there were some elevated distribution kinetics and tissue exposures in the prostate and lung.","label":[[54,57,"Herb name"],[61,65,"Herb name"]],"Comments":[]}
{"id":3495,"text":"Interestingly, the exposures of CIP, GA, and PCA all showed an increase in the prostate tissue after combined administration, which will contribute to the treatment of chronic prostatitis.","label":[[32,35,"Drug"],[37,39,"Herb name"],[45,49,"Herb name"],[168,187,"Pathology"]],"Comments":[]}
{"id":3496,"text":"A meta-analysis of randomized controlled trials of combination therapy indicated that PCE-based products (Relinqing In summary, we focused on the pharmacokinetic herb-drug interactions between PCE and CIP in humans, rats and cells.","label":[[0,47,"Study"],[86,89,"Herb name"],[193,197,"Herb name"],[201,205,"Drug"]],"Comments":[]}
{"id":3497,"text":"The effects of PCE↔CIP presented significantly reduced plasma exposure of CIP and almost unchanged exposure of PCE PK-markers (GA and PCA) in humans and rats.","label":[[15,18,"Herb name"],[19,23,"Drug"],[74,78,"Drug"],[111,115,"Herb name"],[127,130,"Herb name"],[134,137,"Herb name"]],"Comments":[]}
{"id":3498,"text":"The reduced plasma CIP may be attributed to integrated routes mediated by multiple transporters, including BCRP, MDR1, and OAT1\/3.","label":[[19,23,"Drug"],[107,111,"Target"],[113,117,"Target"],[122,129,"Target"]],"Comments":[]}
{"id":3499,"text":"GA and PCA were highly exposed to urogenital tissues after intragastric administration of PCE with or without CIP to rats.","label":[[0,3,"Herb name"],[7,11,"Herb name"],[90,94,"Herb name"],[110,114,"Drug"]],"Comments":[]}
{"id":3500,"text":"Although the decreased circulating CIP seemed not to support the clinical synergism of CIP and PCE, the combined therapy increased the exposure of CIP, GA and PCA in the prostate gland.","label":[[35,39,"Drug"],[87,91,"Drug"],[95,98,"Herb name"],[147,150,"Drug"],[152,155,"Herb name"],[159,163,"Herb name"]],"Comments":[]}
{"id":3501,"text":"The enrichment of these drugs in prostate will be helpful to the treatment of chronic bacterial prostatitis.","label":[[78,107,"Pathology"]],"Comments":[]}
{"id":3502,"text":"Additionally, the effect of combination therapy should pay attention to both the pharmacokinetic- and pharmacodynamic-based interactions, rather than unilaterally.","label":[],"Comments":[]}
{"id":3503,"text":"Further in-depth research should be carried out in the future.","label":[],"Comments":[]}
{"id":3504,"text":"The original contributions presented in the study are included in the article\/Supplementary Material, further inquiries can be directed to the corresponding author.","label":[],"Comments":[]}
{"id":3505,"text":"The studies involving human participants were reviewed and approved by the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine.","label":[],"Comments":[]}
{"id":3506,"text":"The patients\/participants provided their written informed consent to participate in this study.","label":[],"Comments":[]}
{"id":3507,"text":"The animal study was reviewed and approved by the Institutional Animal Care and Use Committee of Tianjin University of Traditional Chinese Medicine.","label":[[0,16,"Study"],[131,139,"Ethnic group"]],"Comments":[]}
{"id":3508,"text":"Conceptualization: ZL, BW, and YH.","label":[],"Comments":[]}
{"id":3509,"text":"Methodology: ZL, XZ, SF, ST, and XD.","label":[],"Comments":[]}
{"id":3510,"text":"Software: ZL and XD.","label":[],"Comments":[]}
{"id":3511,"text":"Validation: ZL and XD.","label":[],"Comments":[]}
{"id":3512,"text":"Formal analysis: ZL and ST. Investigation: ZL, XZ, SF, ST, XD, RW, and YL.","label":[],"Comments":[]}
{"id":3513,"text":"Data curation: ZL, XZ, and SF.","label":[],"Comments":[]}
{"id":3514,"text":"Writing—original draft preparation: ZL and ST. Writing—review and editing: YH.","label":[],"Comments":[]}
{"id":3515,"text":"Visualization: ZL and ST.","label":[],"Comments":[]}
{"id":3516,"text":"Supervision: YL, RW, and BW.","label":[],"Comments":[]}
{"id":3517,"text":"Project administration: YH.","label":[],"Comments":[]}
{"id":3518,"text":"Funding acquisition: ZL, YH, and BW.","label":[],"Comments":[]}
{"id":3519,"text":"All authors have read and agreed to the published version of the manuscript.","label":[],"Comments":[]}
{"id":3520,"text":"The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.","label":[[311,319,"Ethnic group"]],"Comments":[]}
{"id":3521,"text":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","label":[],"Comments":[]}
{"id":3522,"text":"All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.","label":[],"Comments":[]}
{"id":3523,"text":"Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.","label":[],"Comments":[]}
{"id":3524,"text":"The Supplementary Material for this article can be found online at:  Click here for additional data file.","label":[],"Comments":[]}
{"id":3525,"text":"Click here for additional data file.","label":[],"Comments":[]}
{"id":3526,"text":"Click here for additional data file.","label":[],"Comments":[]}
{"id":3527,"text":"Click here for additional data file.","label":[],"Comments":[]}
{"id":3528,"text":" Edited by:   Reviewed by:    This article was submitted to Drug Metabolism and Transport, a section of the journal Frontiers in Pharmacology  Background: Combination of Polygonum capitatum Buch.-Ham.","label":[[170,200,"Herb name"]],"Comments":[]}
